Frontlight ResearchEarly access
WithdrawnPhase 2
Study to Evaluate the Safety, Tolerability, and Efficacy of ASC41 in Adults With NASH
Key facts
- Who runs it
- Gannex Pharma Co., Ltd.
- Trial code
- Status
- Withdrawn
- Phase
- Phase 2
- Started
- 1 Dec 2023
- Ended
- 9 Jan 2025
- Type of study
- Interventional, 4 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- ASC41 2 mg
- ASC41 4 mg
- Placebo
- Record updated
- 27 September 2024
- Why it stopped
- This study has been cancelled due to business reasons
Who can take part
- Age
- 18 years to 80 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Presence of ≥ 8% liver fat content on screening MRI-PDFF
- Histologic evidence of NASH upon central read of a liver biopsy obtained no more than 6 months before Day 1 defined by NASH activity score (NAS) greater than or equal to 4 with at least 1 point each in inflammation and ballooning
- Diabetes Mellitus well controlled based on laboratory test HbA1c ≤ 9.5%
Who cannot take part
- Treatment with vitamin E (unless stable dose of < 400 IU/d), thiazolidinediones (TZD), or glucagon-like peptide-1 receptor agonists (GLP-1 RA), unless subject is on a stable dose for 6 months prior to qualifying liver biopsy
- Use of any investigational drug within 6 months of MRI-PDFF and/or liver biopsy
- Evidence of advanced liver disease such as cirrhosis (stage 4 fibrosis) or decompensated liver disease (e.g. ascites, esophageal varices) or liver cancer
- Evidence of other causes of chronic liver disease
- Known history of alcohol or other substance abuse within the last year or at any time during the study
- Known positivity for antibody to Human Immunodeficiency Virus (HIV)
- Weight change ≥ 5% after qualifying liver biopsy or MRI-PDFF performed
- Any contraindications to a MRI scan
About the trial
What the trial wants to find out
This is a phase 2, randomized, double-blind, placebo controlled study in adults with biopsy confirmed NASH. The study is aimed at evaluating efficacy and tolerability of ASC41 in adults with NASH.
The 4 groups in the trial
- Part 1-ASC41 2mgTreatment being tested
ASC41 2mg for 52 weeks.
Treatment: ASC41 2 mg
- Part1-placeboPlacebo, for comparison
Matching placebo for 52 weeks.
Treatment: Placebo
- Part 2-ASC41 4mgTreatment being tested
ASC41 4 mg for 52 weeks.
Treatment: ASC41 4 mg
- Part2-placeboPlacebo, for comparison
Matching placebo for 52 weeks.
Treatment: Placebo
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Seamless Phase 2a/2b, Double-Blind, Randomized, Multicenter, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Efficacy of ASC41, a Thyroid Hormone Receptor β Agonist, in Adults With Nonalcoholic Steatohepatitis (NASH)
- Record updated
- 27 September 2024